Asteria Health

What Asteria Health does

Asteria Health is a Birmingham, Alabama-based pharmaceutical compounding company that operates as an FDA-registered 503B Outsourcing Facility. Founded in 2017 and operating with 11–50 employees, Asteria specializes in producing compounded bioidentical hormone pellets for hormone replacement therapy, distributing directly to healthcare practitioners and physician practices under cGMP standards. The company is a wholly owned subsidiary of Biote Corp. (NASDAQ: BTMD), and its strategic role within Biote is vertical integration of hormone pellet production for the BHRT franchise.

The company's business model is B2B direct-to-practitioner distribution of compounded hormone pellets. As a 503B outsourcing facility, Asteria is permitted to compound large batches under cGMP and distribute office-use products across state lines — a regulatory posture not available to 503A compounding pharmacies. In August 2025, Asteria announced a strategic partnership with Supply Chain Wizard (SCW) to design and launch a data-driven 503B manufacturing platform, signaling investment in manufacturing analytics, supply chain digitization, and process-data integration. The company has not publicly disclosed standalone revenue; its financials are consolidated within Biote Corp., which reported $44.9M of revenue in Q1 2026.

Asteria's near-term operating profile is shaped by a January 2026 voluntary recall of certain hormone pellet lots due to potential metal particulate contamination, covering product shipped between May 20, 2025 and January 19, 2026. Expected charges are approximately $1.3M in Q4 2025 and $1M across 2026, totaling roughly $2.3M. Leadership disclosed in the input includes Thomas Diamantidis, Founder and Co-CEO/Co-President. The recall introduces near-term quality-control, reputational, and channel-friction risk that will need to be reconciled with the parallel buildout of the data-driven manufacturing platform.

Name

Asteria Health

Legal name

Asteria Health

Website

https://asteriahealth.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

11–50 employees

Short description

Asteria Health is a Birmingham, Alabama-based FDA-registered 503B outsourcing facility that compounds and distributes bioidentical hormone pellets directly to healthcare practitioners. It operates as a wholly owned subsidiary of Biote Corp. (NASDAQ: BTMD), serving the BHRT market.

Ownership category

akta.pro rank

Product category

503B Compounded Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Drug Product Fill-Finish & Aseptic Manufacturing Services (HLAAAKAB)

Keywords

• Pharmaceutical compounding
• Hormone replacement therapy
• 503B outsourcing
• Bioidentical hormones
• Compounded medications

Headquarters

HQ city

Birmingham

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Supply Chain, Technology or R&D, Marketing or Sales

Revenue model

1. 503B Compounded Pharmaceutical Products: Asteria Health generates revenue through the manufacturing and sale of compounded bioidentical hormone pellets to practitioner partners. As a 503B Outsourcing Facility, they produce sterile and non-sterile compounded medications for office use by healthcare providers.

Go-to-market motion1 record

Distribution channels1 record

Core offering

Asteria Health operates an FDA-registered 503B outsourcing facility that manufactures compounded bioidentical hormone pellets distributed to healthcare practitioners. The company focuses on sterile, large-batch production of these hormone pellets under the rigorous regulatory standards required of 503B facilities. Its output supports physicians and practices that prescribe hormone replacement therapy to their patients.

Product overview

Asteria Health operates as a single-focus 503B Outsourcing Facility specializing in the manufacture of compounded bioidentical hormone pellets for hormone replacement therapy. The company provides these products directly to practitioner partners to serve patients requiring hormone treatments. Asteria Health's product portfolio centers on its core pellet manufacturing operations, with a data-driven 503B manufacturing facility in Birmingham, Alabama.

Differentiator

Problem solved

Functional benefit

Products and services

• Compounded Bioidentical Hormone Pellets Sterile, large-batch compounded bioidentical hormone pellets manufactured at the company's 503B outsourcing facility for distribution to physicians and medical practices that prescribe hormone replacement therapy to patients.

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

One partnership is on record.

• Supply Chain Wizard (SCW)coreStrategic or Co-development Partner · 1 August 2025Strategic partnership between Supply Chain Wizard and Asteria Health to launch a data-driven 503B manufacturing facility in Birmingham, Alabama. The collaboration combines SCW's supply chain expertise with Asteria Health's compounding pharmacy capabilities to enhance manufacturing quality, efficiency, and data integration in the 503B outsourcing facility operations.

Scale indicators2 records

Recent moves3 records

Expansion highlights3 records

Direct peers

• QuVa Pharma: QuVa Pharma is one of the largest U.S. 503B outsourcing facilities, providing sterile compounded preparations to hospitals and clinics. Directly comparable to Asteria Health in regulatory model (503B), B2B healthcare distribution, and sterile compounding capability, though at much larger scale and broader product range.
• Leiters: Leiters is a 503B outsourcing facility specializing in sterile compounded preparations, including ophthalmics and injectables. Comparable to Asteria Health in its 503B regulatory positioning, focus on quality-driven sterile compounding, and B2B sales to healthcare practitioners.
• Pharmaceutics International Inc (Pii): Pii is a 503B outsourcing facility focused on aseptic fill-finish and sterile injectable manufacturing. Directly comparable to Asteria Health in its 503B regulatory posture, sterile manufacturing focus, and B2B service to healthcare providers.
• Revelation Pharma: Revelation Pharma operates a national network of 503A and 503B compounding pharmacies serving practitioners and patients with customized medications. Comparable to Asteria Health in compounding-focused business model and practitioner distribution, with overlapping product categories in hormone and sterile preparations.
• Olympia Pharmaceuticals: Olympia Pharmaceuticals operates as a 503B outsourcing facility providing compounded sterile and non-sterile preparations to healthcare providers. Comparable to Asteria Health in 503B regulatory positioning, B2B practitioner distribution, and focus on quality-driven compounded medications.
• Wells Pharma: Wells Pharma operates a 503B outsourcing facility producing sterile injectable and non-sterile compounded preparations for hospitals and clinics. Directly comparable to Asteria Health in 503B outsourcing model, sterile manufacturing capability, and B2B healthcare provider distribution.
• AnazaoHealth: AnazaoHealth is a 503A/503B compounding pharmacy providing customized sterile and non-sterile preparations, including hormone therapies, to practitioners nationwide. Comparable to Asteria Health in compounding focus, hormone therapy offerings, and B2B practitioner distribution.

Broad incumbents

• Central Admixture Pharmacy Services (CAPS): CAPS, a B. Braun company, is a major 503B outsourcing facility providing compounded sterile preparations nationally. Comparable to Asteria in 503B regulatory model and B2B hospital/clinic distribution, but operates as part of a much larger medical products incumbent with broader product breadth.
• Fagron: Fagron is a global leader in pharmaceutical compounding, supplying raw materials, products, and services to compounding pharmacies. Comparable to Asteria Health as a competitor/supplier in the compounding ecosystem with overlapping customer base of practitioners and personalized medicine focus.

Emerging players

• Winged: Winged is an emerging player in the 503B outsourcing space focused on technology-enabled sterile injectable manufacturing. Comparable to Asteria Health in 503B regulatory positioning and B2B healthcare distribution, but represents a newer entrant emphasizing data/automation similar to Asteria's Supply Chain Wizard partnership.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat2 records

Key risks5 records

Key highlights4 records

Customer concentration

• LinkedInlinkedin.com/company/asteria-health

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Asteria Health